NCT01267188View on ClinicalTrials.gov

Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Tardive Dyskinesia
Interventions
DRUG

NBI-98854

powder in bottle, prepared doses at 12.5, 25, and 50 mg q.d. administered for up to 12 days consisting of three treatment periods of 4 days each

Trial Locations (1)

M5T 1R8

Toronto

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY